The July 2025 article entitled “Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults A Randomized Clinical Trial” in JAMA is eye-opening.

A clinical trial finds liver damage in healthy adults taking common CBD doses, often without symptoms. The researchers urge regular testing and medical oversight, especially as CBD use grows rapidly, in spite of limited proof of benefits or long-term safety.

The Study Overview

  • Design: Double‑blind, placebo‑controlled randomized clinical trial
  • Participants: 201 healthy adults (age 18–55), non–tobacco, non–alcohol users, no pre-existing liver or serious medical conditions
  • Intervention: Pharmaceutical-grade CBD at 2.5 mg/kg twice daily (totaling 5 mg/kg/day), compared with placebo over 28 days.

The Key Findings

  • Liver enzyme elevations:
    • 8 of 151 participants (~5.6%) in the CBD group exhibited >3× increase in ALT/AST
    • No such elevations in the 50-person placebo group
  • Drug-induced liver injury:
    • Seven participants met criteria for potential liver injury—2 on day 21, 5 on day 28
  • Hormones unaffected:
    • Male reproductive hormones (testosterone, inhibin B) and thyroid function showed no changes.

The Implications

  • High doses of CBD (5 mg/kg/day) can pose a risk: In healthy individuals, significant liver enzyme elevations were evident in about 1 in 18 participants over just four weeks
  • Need for caution in real-world use: Current consumer doses and durations are typically much lower, but this study suggests the importance of monitoring, especially with prolonged use or pre-existing liver conditions
  • Further research needed: To determine safe dosage, duration, and conditions under which CBD may affect liver health.

The Net Net

This well‑controlled short-term trial found that high-dose CBD led to clinically relevant elevations in liver enzymes in healthy adults—a signal that warrants cautious use and more extensive studies, especially with longer treatment courses or higher-risk populations.

This is image below is from (2024: “The Role of Cannabidiol in Liver Disease: A Systemic Review“)–